Bladder Cancer Clinical Trials
Urothelial/Bladder Cancer
Learn More About Bladder Cancer
For general information on bladder cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| ADCE-B05-001 | Urothelial/Bladder Cancer | A First-in-Human, Phase 1a/1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients with Advanced Solid Tumors | Immunotherapy | ADC anti-GPC1 IgG1 with a Topo-I inhibitor and P1021 | Open - Recruiting | Adcendo ApS | NCT07362888 | Enquire Now |
| SL-28-FIH | Urothelial/Bladder Cancer | A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours | Immunotherapy | IV allogeneic, non-genetically modified cell-based therapy | Open - Recruiting | Second Life Therapeutics Pty Ltd. | ACTRN12625001342404p | Enquire Now |